Description
Product Name: | Anti-Human CD279 (PD-1) (Nivolumab) - Dylight 488 |
SKU: | IVMB0437 |
Size: | 100 µg |
Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
Clone: | 5C4.B8 |
Target: | PD-1 |
Isotype: | Human IgG1κ |
Host Species: | Human |
Reactivity: | Human/Cynomolgus Monkey |
Applications: | FA |
Expression Host: | HEK-293 Cells |
FC Effector Activity: | Active |
Synonyms: | PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; hSLE1 |
Product Concentration: | 0.2 mg/ml |
Excitation Laser: | Blue Laser (493 nm) |
Immunogen: | Human PD-1 |
Applications and Recommended Usage: | FC The suggested concentration for Nivolumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. |
Antigen Distribution: | PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells. |
Formulation: | This DyLight 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Nivolumab. Clone 5C4.B8 binds to the extracellular portion of Human/Cynomolgus PD-1 and does not bind to other IgG superfamily proteins. This product is for research use only. |
Additional Applications Reported In Literature: | IHCFA |
Additional Reported Applications For Relevant Conjugates: | B |
Programmed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance. PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity. PD-L1 and PD-L2 are the two ligands known to bind PD-1. PD-L1 has increased expression in several cancers.1 PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity.2 Nivolumab disrupts the negative signal that is responsible for T-cell activation and proliferation by binding to PD-1 on activated immune cells to selectively block the interaction of the PD-1 receptor with its ligands.3 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with nivolumab and ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.4 This cost-effective, research-grade Anti-Human CD279 (PD-1) (Nivolumab) utilizes the same variable regions from the therapeutic antibody Nivolumab making it ideal for research projects.
Ligand/Receptor: | PD-L1 and PD-L2 |
Regulatory Status: | Research Use Only (RUO). Non-Therapeutic. |
Storage and Handling: | This DyLight 488 conjugate is stable when stored at 2-8°C.Do not freeze. |
Research Area: | Biosimilars |